Virologically suppressed patients with asymptomatic and symptomatic HIV‐associated neurocognitive disorders do not display the same pattern of immune activation

• Published in: HIV medicine Vol. 16; no. 7; pp. 431 - 440
• Main Authors: Vassallo, M, Durant, J, Lebrun‐Frenay, C, Fabre, R, Ticchioni, M, Andersen, S, DeSalvador, F, Harvey‐Langton, A, Dunais, B, Cohen‐Codar, I, Montagne, N, Cua, E, Fredouille‐Heripret, L, Laffon, M, Cottalorda, J, Dellamonica, P, Pradier, C
• Format: Journal Article
• Language: English
• Published: England 01.08.2015
• Subjects: AIDS Dementia Complex - drug therapy; AIDS Dementia Complex - immunology; AIDS Dementia Complex - physiopathology; CD4-CD8 Ratio; Cognition Disorders - drug therapy; Cognition Disorders - immunology; Cognition Disorders - physiopathology; Cross-Sectional Studies; Female; France - epidemiology; HIV‐associated neurocognitive disorders; Humans; immune activation; Logistic Models; Lymphocyte Activation - drug effects; Lymphocyte Activation - immunology; Male; Middle Aged; Predictive Value of Tests; Risk Factors; Viral Load; France; CD4:CD8 ratio; HIV-associated neurocognitive disorders; immune activation
• DOI: 10.1111/hiv.12246
• ISSN: 1464-2662; 1468-1293

Objectives Inversion of the CD4:CD8 ratio is a marker of immune activation and age‐associated disease. We measured the CD4:CD8 ratio as a marker of cognitive impairment in HIV‐infected patients and explored differences according to clinical severity. Methods Post hoc analysis of data from two prospective cohorts of HIV‐infected patients randomly selected to undergo neuropsychological tests was performed. Test scores were adjusted for age, gender and education. Inclusion criteria were undetectable viral load and stable treatment for at least 6 months. Subjects with HIV‐associated dementia were excluded. Patients were divided into an unimpaired group, a group with asymptomatic neurocognitive disorder (ANI) and a group with symptomatic HIV‐associated neurocognitive disorder (sHAND), represented by mild neurocognitive disorder (MND). Demographic and background parameters, immune activation markers and the CD4:CD8 ratio were recorded. Results Two hundred patients were included in the study. The mean age was 52 years, 78% were male, the mean CD4 count was 624 cells/μL, the mean nadir CD4 count was 240 cells/μL, 27% were hepatitis C virus (HCV)‐coinfected, the mean duration of HIV infection was 16 years, and the mean time on current combination antiretroviral therapy (cART) was 2.9 years. Twenty‐nine per cent of subjects had HAND (21% had ANI and 8% had MND). In multivariate analysis, a CD4:CD8 ratio < 1 was associated with a nadir CD4 count < 200 cells/μL [odds ratio (OR) 3.68] and with the presence of CD4+CD38+HLA+ cells (OR 1.23). Multinominal logistic regression showed that, in comparison with the unimpaired group, diagnosis of sHAND was associated with a CD4:CD8 ratio < 1 (OR 10.62), longer HIV infection (OR 1.15) and longer current cART (OR 1.34), while the ANI group differed from the unimpaired group only for education level. Conclusions Aviraemic patients with sHAND did not display the same pattern of immune activation as subjects with ANI, suggesting that the underlying pathophysiological mechanisms could be different.